ClinicalTrials.gg

TargetBeta

JAK3

Janus kinase 3 · also L-JAK, JAKL, LJAK, JAK3_HUMAN · Jak family tyrosine kinases

8 programs in company-led studies act on JAK3, from 7 companies: 4 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
upadacitinibruleAbbViephase 46424 runningJAK1, JAK2, TYK2ChEMBL
ruxolitinibruleIncytephase 49518 runningJAK1, JAK2, TYK2ChEMBL
tofacitinibrulePfizerphase 4943 runningJAK1, JAK2, TYK2ChEMBL
filgotinib maleateruleEisaiphase 421 runningJAK1, JAK2, TYK2ChEMBL
ritlecitinibrulePfizerphase 3428 runningBMX, BTK, ITK, TEC, TXKNCIt
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 3318 runningFLT3, JAK1, JAK2the studies' text
filgotinibruleLakefront Biotherapeutics NVphase 3464 runningJAK1, JAK2, TYK2ChEMBL
delgocitinibruleLEO Pharmaphase 3212 runningJAK1, JAK2, TYK2ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.